Cargando…
Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group
Fabry disease (FD) [OMIM 301500] is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, resulting in progressive multisystem accumulation of globotriaosylceramide (Gb3). Although the introduction of Enzyme Replacement Therapy (ERT) resulted in...
Autores principales: | Concolino, D., Amico, L., Cappellini, M.D., Cassinerio, E., Conti, M., Donati, M.A., Falvo, F., Fiumara, A., Maccarone, M., Manna, R., Matucci, A., Musumeci, M.B., Nicoletti, A., Nisticò, R., Papadia, F., Parini, R., Peluso, D., Pensabene, L., Pisani, A., Pistone, G., Rigoldi, M., Romani, I., Tenuta, M., Torti, G., Veroux, M., Zachara, E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484973/ https://www.ncbi.nlm.nih.gov/pubmed/28702361 http://dx.doi.org/10.1016/j.ymgmr.2017.06.005 |
Ejemplares similares
-
Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects
por: Piatti, G., et al.
Publicado: (2022) -
Gastrointestinal Symptoms of Patients with Fabry Disease
por: Pensabene, Licia, et al.
Publicado: (2016) -
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017) -
Enzyme replacement therapy: efficacy and limitations
por: Concolino, Daniela, et al.
Publicado: (2018) -
Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
por: Tomanin, Rosella, et al.
Publicado: (2014)